List of Research Projects

Current Ongoing Research Projects 2014

1. Evaluation of Patient Decision Aid for Localized Prostate Cancer Patientsin Referral Hospitals in Peninsular Malaysia (NMRR no: 14-494-20143) (start date: August 2014).

2. Pharmacogenetics of prostate cancer; Principal investigator: Prof. Azad Hassan Abdul Razack; Funding body: University of Malaya HIR grant.

3. Study on the role of CYP450 gene polymorphisms, frequency of TMPRSS2/ERG fusion and their associations with hormonal and IGF profiles in the risk of prostate cancer development in multiethnic Malaysian and Western populations; Principal investigator: Prof. Azad Hassan Abdul Razack; Funding body: University of Malaya HIR grant.

4. A randomized, double-Blind, parallel-group, placebo- and active-controlled, multi-centre study to evaluate the efficacy, safety and tolerability of combinations of solifenacin and mirabegron compared to solifenacin succinate and mirabegron monotheraphy in the treatment of overactive bladder (Phase III); Principal investigator: Prof. Azad Hassan Abdul Razack; Funding body: Astellas Pharma Europe B.V.

5. Large scale profiling of cancer/testis antigen (CTA) and the delineation of MiRNA-mediated reversal of CTA-associated aberrant demethylation in urothelial cell carcinoma; Principal investigator: Assoc. Prof. Ong Teng Aik; Funding body: University of Malaya HIR grant.

6. Urinary tract and liver injury from long term oral ketamine and its reversibility in a rat model; Principal investigator: Assoc. Prof. Ong Teng Aik; Funding body: University of Malaya UMRG grant.

7. The mechanism of ketamine cystitis in a rat model; Principal investigator: Assoc. Prof. Ong Teng Aik; Funding body: University of Malaya Global Collaborative Program.

8. A phase 3 randomized, double blind, comparative study of abiraterone acetate  (JNJ-212082) plus low dose prednosolone plus androgen deprivation therapy vs ADT alone in newly diagnosed subjects with high risk metastatic hormone naïve prostate  (mHNPC); Co- investigator: Assoc. Prof. Ong Teng Aik; Funding body: Janssen (Latitude trial).

9. A multinational phase 3 randomized, double-blind, placebo controlled, efficacy and safety of enzalutamide in patient with non metastatic castration resistant prostate cancer; Co- investigator: Assoc. Prof. Ong Teng Aik; Funding body: (Prosper trial).

10. Better molecular signature for renal onco cytomas vs. chromophobe RCC; Principal investigator: Dr. Ahmad Nazran Fadzli; Funding body: University of Malaya BKP grant.

11. Efficacy of oral chondrotin sulphate (Urosulf TM) in reducing ureteric stent related symptoms; Principal investigator: Dr. Ahmad Nazran Fadzli; Funding body: Advance Pharma Sdn Bhd.

12. Prevalence of HPV in foreskin of prepubertal boys in Malaysia; Principal investigator: Dr. Siti Nur Masyithah binti Ma’arof; Funding body: University of Malaya BKP grant.

13. NFkB and TRAF1 expression in renal cell carcinoma; Principal investigator: Dr. Retnagowri Rajandram; Funding body: University of Malaya UMRG grant.

14. Biomarker discovery in renal cell carcinoma; Principal investigator: Dr. Retnagowri Rajandram; Funding body: Malaysian Ministry of Science, Technology and Innovation MOSTI grant.

15. Deciphering the molecular mechanisms and therapeutic potential of Traf1 and Nf-Kb in renal cell carcinoma; Principal investigator: Dr. Retnagowri Rajandram; Funding body: Malaysian Ministry of Education FRGS grant.

16. Automated medical imaging diagnostic based on four critical diseases: brain, breast, prostate and lung cancer; Funding body: Arus Perdana grant.

17. Urethral reconstruction via tissue engineering; Funding body: Dana Lonjakan Penerbitan.

18. A randomized, double-blind, parallel-group, placebo- and active- controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder; Principal investigator: Prof. Azad Hassan Abdul Razack; Funding body: Astellas Pharma Europe B.V. (APEB).

19. The effect of oral sildenafil citrate on macular thickness and multifocal electroretinogram (mfERG) of type 2 diabetes; No funding body.


  printer Printer-friendly version   printer Send link to a friend